Navigation Links
Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
Date:12/6/2009

NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients. These data were presented today at the ASH/ASCO Joint Symposium at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. Enrollment in this trial is complete (n=269), and full results, expected in 2010, could support a potential new drug application (NDA) filing by year-end 2010.

"These results show that carfilzomib is well-tolerated and can be administered at a full dose over a long period of time even in a very sick patient population for whom all available treatment options have been exhausted and who have multiple comorbidities," said lead investigator Sundar Jagannath, M.D., chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York. "We look forward to the full data from this trial next year."

Dr. Jagannath also presented results from the Phase 2 003-A0 study, which recruited patients whose myeloma had relapsed from two or more prior therapies and was refractory to their previous therapy. This study is the lead-in study for the current Phase 2b registrational trial in the same population. Data from this study was initially presented at the American Society for Clinical Oncology (ASCO) annual meeting in June 2009. Patients in the study had a median of five prior therapies. Previously presented efficacy data from 39 evaluable patients in the 003-A0 pilot study included an 18 percent overall response rate (partial response or better) and a 26 percent clinical benefit rate (minor response or better
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
2. More proof needed of safety and quality of electronic personal health records
3. Back to School Means Backpack Safety
4. Seniors Need a Safety Plan in Face of Disasters
5. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
6. National Patient Safety Foundation Partners with Vocera Communications
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... December 22, 2014 BellasDress.com offers a ... for women. Today, it announces its BellasDress Christmas ... at its online store. , BellasDress is a famous ... to its fans through a series of promotions. The ... every customer. , “We are proud of offering ...
(Date:12/21/2014)... New York (PRWEB) December 21, 2014 ... and other product liability claims involving a class ... mimetics continue to move forward in a federal ... Southern District of California, Bernstein Liebhard LLP reports. ... Court has established a data cut-off date of ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas joy ... helping people get their health back. Mission for area ... those persons in Muskegon County who are unable to find ... life. Dr. Michael Rykse wanted to do a Toy Drive ... he knew he found that when he heard what MAP ...
(Date:12/21/2014)... SCI explores disability in sports ... barriers for disabled athletes with Aaron Scheidies , ... condition called juvenile macular degeneration, where he loses his ... his athletic ambitions to his vision and how he ... pioneer the way for other blind and visually impaired ...
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... , , , ... August 3 Zogenix, Inc. ("Zogenix"), a privately held ... today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan ... approval in July 2009 and is a first-of-its-kind needle-free ...
... , MONDAY, Aug. 3 (HealthDay News) -- Common variants of ... increased risk of pancreatic cancer, according to U.S. researchers. , ... patients and more than 4,500 people without the disease. This ... that produce the blood types A, B or AB are ...
... enough , MONDAY, Aug. 3 (HealthDay News) -- Most American ... associated with an increased incidence of risk factors for cardiovascular ... find. , Simultaneous publication of both papers in the Aug. ... lead authors of the reports said. Both used U.S. data ...
... study published in the August issue of The Journal ... is an important tool for depicting the extent of neuroblastoma ... of the disease. Neuroblastoma accounts for six to ten percent ... percent of cancer deaths in children. Accurately identifying where in ...
... , BOSTON, Aug. 3 AMICAS, Inc. (Nasdaq: ... solutions, today announced a new contract with The Hospital of Central ... Connecticut to achieve its reading, productivity, and critical results management goals. ... ) , , The Hospital of ...
... , WALTHAM, Mass., Aug. 3 ... advisory firms for pharmaceutical and healthcare issues, finds that, from ... cause a decline of more than eight percent in the ... tract symptoms in the United States, France, Germany, Italy, Spain, ...
Cached Medicine News:Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:Blood Type May Boost Pancreatic Cancer Risk 2Health News:Vitamin D Deficiency Linked to Heart Risk Factors in Kids 2Health News:Vitamin D Deficiency Linked to Heart Risk Factors in Kids 3Health News:PET can help guide treatment decisions for a common pediatric cancer 2Health News:The Hospital of Central Connecticut Chooses AMICAS 2Health News:The Hospital of Central Connecticut Chooses AMICAS 3Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 2Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 3
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , ... SRNE ;  Sorrento), an oncology company ... and Conkwest, Inc., a privately-held immuno-oncology company developing ... (NK) cell-line based therapy, announced today that the ... jointly develop next generation CAR-TNK™ (pronounced as "Car-Tank") ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  Sage ... new generation of equipment for the testing of ... release of the new Luminary™ Profiler, the industry,s ... light-based measurement in a cost-effective, portable unit. ... the specific needs of the cannabis industry, the ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... , WOODCLIFF LAKE, N.J., Nov. 16 Eisai Inc. ... available for use by persons trained in the administration ... intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) ... The U.S. Food and Drug Administration (FDA) approved LUSEDRA ...
... , LOS ANGELES, Nov. 16 Cardo Medical, ... company based in Beverly Hills, California, announced today that ... in which it successfully raised approximately $6.2 million in ... , Cardo Medical, Inc. intends to use the proceeds ...
Cached Medicine Technology:LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available 2LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available 3Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement 2Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
Medicine Products: